|
1.
Dajani EZ: Studies on the toxicology and central nervous
system pharmacology of ethylene glycol monomethyl ether in rats and
mice. Unpublished Ph.D.
thesis, Purdue
University,
1968.
2.
Dajani EZ, Driskill DR, Bianchi RG, Collins PW: Comparative
gastric antisecretory and antiulcer effects of Prostaglandin
E1 and its methyl ester in animals. Prostaglandins
10:205-216, 1975.
3.
Dajani EZ, Driskill
DR, Bianchi RG,
Collins PW, Pappo R: Influence of the position of the side chain
hydroxy group on the gastric antisecretory and anti-ulcer actions of
E1 prostaglandin analogs. Prostaglandins
10:733-745, 1975.
4.
Sanvordeker DR, Dajani EZ: In vitro adsorption of
diphenoxylate hydrochloride on activated charcoal and its
relationship to pharmacological effects of the drug in vivo. J Pharm
Sci 64:1877-1879, 1975.
5.
Dajani EZ, Roge EAW, Bertermann RE: Effects of
E-prostaglandins, diphenoxylate and morphine on intestinal motility
in vivo. Europ J
Pharmacol 34:105-113, 1975.
6.
Collins PW, Dajani EZ, Bruhn MS, Brown CH, Palmer JR, Pappo
R: Influence of the position of the side chain hydroxyl group on the
biological properties of prostaglandins. Tetrahedron Letters
48:4217-4220, 1975.
7. Bruhn
M, Brown CH, Collins PW, Palmer JR, Dajani EZ, Pappo R: Synthesis
and properties of 16-hydroxy analogs of PGE2. Tetrahedron Letters
4:235-238, 1976.
8.
Dajani EZ, Callison DA, Bianchi RG,
Driskill
DR: Gastric
antisecretory effects of E-prostaglandins in rhesus monkeys. Dig Dis and Sci
21:1020-1028, 1976.
9.
Dajani EZ, Callison DA: Gastric antisecretory actions of
15(S) 15-methyl prostaglandin E2 methyl ester and natural
prostaglandin E2 in rhesus monkeys. Prostaglandins
11:799-808, 1976.
10. Dajani EZ,
Driskill DR, Bianchi RG, Collins PW, Pappo R: SC-29333, a potent
inhibitor of canine gastric secretion. Dig Dis Sci
21:1049-1057, 1976.
11. Mackerer
CR, Clay GA, Dajani EZ: Loperamide binding to opiate receptor sites
of brain and myenteric plexus.
J Pharmacol Exp Therap 199:131-140,
1976.
12. Dajani EZ,
Rozek LF, Sanner JH, Miyano M: Synthesis and biological evaluation
of W-homologues of prostaglandin E1. J Med Chem
19:1007-1010, 1976.
13.
Adelstein GW, Yen CH, Dajani EZ, Bianchi RG: 3,3-Diphenyl-3
(2-alkyl-1,3,4-Oxadiazol-5-yl) propylcycloalkylamines: A novel
series of anti-diarrheal agents. J Med Chem
19:1221-1225, 1976.
14. Dajani EZ,
Bianchi RG, East PF, Bloss JL, Adelstein GW, Yen CH: The
pharmacology of SC-27166: A novel anti-diarrheal agent. J Pharmacol Exp Therap
203:512-526, 1977.
15.
Dajani EZ, Driskill
DR: Effects of
7-oxa-13-prostynoic acid (7-OPyA) and prostaglandin E1
methyl ester on canine gastric secretion. Prostaglandins
14:659-665, 1977.
16. Collins PW,
Dajani EZ, Driskill DR, Bruhn MS, Jung CJ, Pappo R: Synthesis and
gastric antisecretory properties of 15-deoxy,
16-hydroxy E-prostaglandin analogs. J Med Chem
20:1152-1159, 1977.
17. Mackerer
CR, Brougham LR, East PF, Bloss JL, Dajani EZ, Clay GA: The binding
of SC-27166
[2-[3,3-diphenyl-3-(2-methyl-1,3,4-oxadiazol-5-yl)propyl]-azabicyclo
[2.2.2] Octane], a new antidiarrheal agent, to opiate receptor sites
of brain and myenteric plexus.
J Pharmacol Exp Therap 203:527-538,
1977.
18. Dajani EZ,
Callison DA, Bertermann RE: Effects of E-prostaglandins on canine
gastric potential difference.
Dig Dis Sci 23:436-442,
1978.
19. Dajani EZ,
Callison DA, Bianchi RG: Gastric antisecretory effects of
propantheline bromide and metiamide in rhesus monkeys. Arch Int
Pharmacodyn Therap 234:107-117,
1978.
20. Dajani EZ,
Driskill D: Effect of oral and intravenous propantheline bromide on
pentagastrin-stimulated canine gastric secretion. Arch Int Pharmacodyn Therap
233:243-250, 1978.
21. Colton DG,
Driskill DR, Phillips EL, Poy P, Dajani EZ: Effect of SC-29333, an
inhibitor of gastric secretion, on canine gastric mucosal blood flow
and serum gastrin levels.
Arch Int Pharmacodyn et Therap 236:86-95,
1978.
22. Dajani EZ,
Bertermann, RE, Roge EAW, Schweingruber
FL, Woods EM:
Canine gastrointestinal motility effects of prostaglandin
F2 alpha in vivo.
Arch Int Pharmacodyn Therap 237:16-24,
1979.
23. Dajani EZ,
Bianchi RG, Calhoun DW: Synergistic actions of propantheline bromide
with cimetidine and thiopropazate hydrochloride in the prevention of
stress ulcer formation in rats. J Pharmacol Exp Therap
210:373-377, 1979.
24. Colton DG,
Callison DA, Dajani EZ: Effects of prostaglandin E1
derivative, SC-29333, and aspirin on gastric ionic fluxes and
potential difference in dogs.
J Pharmacol Exp Therap 210:283-288,
1979.
25. Dajani EZ,
Woods EM, Roge EAW, Bertermann RE, Schweingruber
FL: Naloxone
reversal of drug-induced diarrhea in mice. Arch Int Pharmacodyn Therap
240:340-350, 1979.
26. Dajani EZ,
Bianchi RG, Casler JJ, Weet JF: Gastric antiulcer and antisecretory
effect of carbenoxolone, aldosterone and desoxycorticosterone in
rats. Arch Int
Pharmacodyn Therap
242:128-138, 1979.
27. Gullikson
GW, Dajani EZ, Bianchi RG: Inhibition of intestinal secretion in the
dog: A new approach for the management of diarrheal states. J Pharmacol Exp Therap
219:591-597, 1981.
28. Dajani EZ,
Driskill DR, Bianchi RG, Phillips EL, Woods EM, Colton DG, Collins
PW, Pappo R: Effect of prostaglandin analogue, SC-30249, on canine
gastric secretion. Drug
Dev Res 3:339-347, 1983.
29. Collins PW,
Dajani EZ, Pappo R, Gasiecki AF, Bianchi RG, Woods EM: Synthesis and
gastric antisecretory properties of 4,5 unsaturated derivatives of
15-deoxy-16-hydroxy-16-methyl prostaglandin E1. J Med Chem
26:786-790, 1983.
30. Dajani EZ,
Nissen
CA: Investigations
of the gastrointestinal cytoprotective effects of misoprostol:
Clinical efficacy overview.
Dig Dis Sci 30:194S-200S,
1985.
31. Collins PW,
Pappo R, Dajani EZ: Chemistry and synthetic development of
misoprostol. Dig Dis
Sci 30:114S-117S, 1985.
32. Sontag SJ,
Mazure PA, Pontes JF, Beker SG, Dajani EZ: Misoprostol in the
treatment of duodenal ulcer: A multi-center, double-blind,
placebo-controlled study.
Dig Dis and Sci 30:159S-163S,
1985.
33. Agrawal NM,
Saffouri B, Kruss DM, Callison DA, Dajani EZ: Healing benign gastric
ulcer: A placebo-controlled comparison of two misoprostol dosage
regimens. A synthetic
analog of prostaglandin E1. Dig Dis Sci
30:164S-170S, 1985.
34. McGuigan
JE, Chang Y, Dajani EZ: Effect of misoprostol, an antiulcer
prostaglandin, on serum gastrin in patients with duodenal
ulcer. Dig Dis Sci
31:120S-125S, 1986.
35. Dajani EZ:
Is peptic ulcer a prostaglandin deficiency disease? An
editorial. Human
Pathology 17:106-107, 1986.
36. Agrawal NM,
Godiwala T, Arimura A, Dajani EZ: Cytoprotection against
ethanol-induced gastric mucosal damage by a synthetic prostaglandin:
A double blind endoscopic study in human subjects. Gastrointestinal Endoscopy
32:67-70, 1986.
37.
Dajani EZ: Prostaglandins, ASA and mucosal damage. Arzneim Forsch/Drug Research
36:1150-1151, 1986.
38. Gullikson
GW, Anglin C, Kessler L, Smeach S, Bauer R, Dajani EZ: Misoprostol
attenuates aspirin-induced changes in potential difference and
associated damage in canine Heidenhain pouches. Clinical Invest Med.
10: 145-151, 1987.
39. Bertaccini
G, Dajani E, Paoletti R, Watkinson G: Prostaglandins in
gastroenterology--Focus on Misoprostol--Forward. Prostaglandins 33
(Suppl.): 1, 1987.
40. Dajani EZ:
Perspective on the gastric antisecretory effects of misoprostol in
man. Prostaglandins
33 (Suppl.): 68-77, 1987.
41. Reimann HJ,
Lewin T. Schmidt U, Wendt P, Blueml G, Dajani EZ: Misoprostol
prevents damage to the gastric mucosa by stabilizing the mast
cells. Prostaglandins
33 (Suppl.):105-116, 1987.
42. Dajani EZ:
Overview of the mucosal protective effects of misoprostol in
man. Prostaglandins
33 (Suppl.):117-129, 1987.
43. Godiwala T,
Agrawal
NM, Groot K,
Arimura, Dajani EZ: Is cytoprotection by misoprostol against
ethanol-induced gastric mucosal injury in man mediated by
somatostatin?
Prostaglandins 33 (Suppl.):130-131,
1987.
44. Davis GR,
Fordtran JS, Dajani EZ: Dose-response, meal-stimulated gastric
antisecretory study of prostaglandin E1 analog,
misoprostol, in man.
Dig Dis Sci 33:298-302,
1988.
45. Agrawal NM,
Godiwala T, Arimura A, Groot K, Dajani EZ: Protective effects
against alcohol insult: Does somatostatin play any role? Post Graduate Medical
Journal 64 (Suppl. 1):15-18,
1988.
46. Dajani EZ:
Prostaglandins: Pharmacology, mechanism and applications in peptic
ulcer disease. Chinese
J Clin Pharmacol 5 (2):102-117,
1989.
47. Dajani EZ,
Agrawal
NM: Protective and
therapeutic effects of prostaglandins. Clin Pharmacol Res
9(6): 359-369, 1989.
48. Agrawal NM,
Dajani EZ: Treatment and prevention of nonsteroidal
anti-inflammatory drug-induced gastrointestinal mucosal injury. Clin Pharmacol Res 9
(6): 347-357, 1989.
49. Dajani EZ:
Mucosal defense and concept of cytoprotection. An Editorial. Modern Pathology
3:3-4, 1990.
50. Agrawal NM,
Dajani EZ: Options in the treatment and prevention of NSAID-induced
gastroduodenal mucosal damage.
J Rheumatology 17 (Suppl): 7-11,
1990.
51. Dajani EZ,
Agrawal
NM: Nonsteroidal
anti-inflammatory drug-induced gastrointestinal damage in the
elderly: Pathogenesis and therapeutic considerations. Internal Medicine for the
Specialist 11 (9): 91-110,
1990.
52. Dajani EZ,
Wilson DM, Agrawal
NM:
Prostaglandins: An overview of the worldwide clinical
experience. J Assoc
Acad Min Physicians 2:23-25,
1991.
53. Dajani EZ,
Penin VA, Sokolov LK, Vahtangishvilli R, Bogdanov A, Afonskaya N.
Ivanishvilli L, Zharova Y., Efremova I: Misoprostol and dalargin for
the in-patient treatment of duodenal ulcer in the U.S.S.R. J Assoc Acad Min Physicians
2:18-22, 1991.
54. Dajani EZ:
Review of book entitled "Clinical Investigation of gastric
function."
Gastroenterology 100:1478-1479,
1991.
55. Agrawal NM,
Patel R, Mahatma M, Dajani EZ: Nonsteroidal anti-inflammatory drugs
and acute upper gastrointestinal bleeding: A prospective study. J Assoc Acad Min Physicians
2:64-66, 1991.
56. Dajani EZ:
Misoprostol: Pharmacology, pharmacokinetics and mechanisms of
action. Experimental
and Clinical Gastroenterology 1:97-106,
1991.
57. Mahatma M.
Agrawal N, Dajani EZ, Nelson S, Nakamura C, Sitton J: Misoprostol
but not antacid prevents endotoxin-induced gastric mucosal injury:
Role of tumor necrosis factor-alpha. Dig Dis Sci
36:1562-1568, 1991.
58. Dajani EZ,
Straus E: Editorial Overview.
In: Updates in
Acid Peptic Disorders.
Eds. Dajani EZ,
Straus EW: A special edition of the J Assoc Acad Minority Physicians
3:69, 1992.
59. Dajani EZ,
Trotman BW: Drugs for the treatment of peptic ulcers. In: Updates in Acid Peptic
Disorders. Eds. Dajani EZ, Straus EW: A special edition of the J
Assoc Academic Mino Physicians 3:78-88,
1992.
60.
Arakawa T,
Kobayashi K, Dajani EZ: Refractory peptic ulcers. In: Updates in Acid Peptic
Disorders. Eds. Dajani
EZ, Straus EW: A Special edition of the J Association for Academic
Minority Physicians 3: 95-102, 1992.
61.
Agrawal NW,
Dajani EZ: Prevention and treatment of ulcers induced by
nonsteroidal anti-inflammatory drugs. J Assoc Acad Minority
Physicians 3: 142-148, 1992.
62.
Larsen KR, Dajani EZ, Ives MM: Anti-ulcer drugs and gastric
mucosal injury: Effects of misoprostol, 16,16-dimethyl
PGE2 and cimetidine on hemodynamics and metabolic rate in the canine
gastric mucosa. Dig Dis
Sci 37: 1029-1038, 1992.
63. Dajani EZ,
Wang B, Pei Y, Pan G, Chen S, Zheng Z, Li Y, Zhu W, Wang J, Yuan S,
Yu Y, Yao ZJ: Misoprostol in the treatment of duodenal ulcers in the
People's Republic of China: A comparative,
double-blind multicenter study. Drug Development Research
27: 415-423, 1992.
64. Dajani EZ:
Omega-3 fatty acids and bowel cancer. Gastroenterology
104:1239-1240, 1993.
65. Dajani EZ:
Future treatment of peptic ulcer: Is there room for the
anti-infective drugs?
An editorial. J Physiology and Pharmacology 44:3-6,
1993.
66. Juhl CO,
Vinter-Jensen L, Jensen LS, Nexo E, Djurhuus JC, Dajani EZ: Systemic
treatment with recombinant human epidermal growth factor accelerates
healing of sclerotherapy-induced esophageal ulcers and prevents
esophageal stricture formations in pigs. Dig Dis Sci 39:
2671-2678, 1994.
67. Juhl CO,
Vinter-Jensen L, Jensen LS, Nexo E, Djurhuus JC, Dajani EZ:
Biomechanical properties of the oesophagus damaged by sclerotherapy:
An impedance planimetric study in minipigs. Scand J Gastroenterol 29:
867-873, 1994.
68.
Vinter-Jensen L, Frokiaer J, Jorgensen PE, Marqversen J,
Rehling M, Dajani EZ, Nexo E: Tissue distribution of 131-I-labelled
epidermal growth factor in pig visualized by dynamic
scintigraphy. J
Endocrinology 144: 5-12, 1995.
69. Dajani EZ,
Agrawal
NM: Prevention on
nonsteroidal anti-inflammatory drug-induced gastroduodenal ulcers:
Role of mucosal protective and gastric anti-secretory drugs. Digestive Diseases 12
(Suppl 1): 46-61, 1995.
70. Dajani EZ,
Agrawal
NM: Prevention and
treatment of NSAID-induced ulcers: An update. J Physiol Pharmacol
46: 3-16, 1995.
71.
Vinter-Jensen L, Juhl CO, Eika B, Gregersen H, Dajani EZ:
Epidermal growth factor attenuates the sclerotherapy associated
biomechanical properties of the oesophagus: An experimental study in
minipigs. Scand J
Gastroenterol 30: 614-619, 1995.
72.
Vinter-Jensen L, Juhl CO, Rehfeld JF, Poulsen SS, Dajani EZ,
Nexo E: Chronic treatment with epidermal growth factor induces
hypergastrinemia in pigs.
Scand J Gastroenterol 30: 422-427, 1995.
73. Vinter-Jensen L,
Juhl CO, Djurhuus JC, Dajani EZ, Teglbjaerg PS, Uvelius, Nexo E:
Ureteric growth in Gottingen minipig induced by epidermal growth
factor. A case report. Scand J Urol Nephrol Suppl 172:
109-115, 1995.
74. Juhl
CO, Vinter-Jensen L, Jensen LS, Dajani EZ, Nexo E: Preventive
effects of recombinant human epidermal growth factor on the
esophageal epithelium in pigs subjected to sclerotherapy. Europ J Hepatol Gastroentero
l 7: 823-828, 1995.
75.
Vinter-Jensen L, Juhl CO, Djurhuus JC, Poulson SS, Dajani EZ,
Brown KD, Orntoft TF, Teglbjaerg PS, Nexo E: Chronic Systemic
treatment with epidermal growth factor in pigs causes pronounced
urothelial growth with accumulation of glycoconjugates. Am J Pathol 147:
1330-1338, 1995.
76. Juhl
CO, Vinter-Jensen L, Myhre-Jensen O, Jensen LS, Dajani EZ: Systemic
treatment with epidermal growth factor in pigs induces anemia in
Gottington pigs. Clinical Sciences 89: 453-458,
1995.
77.
Vinter-Jensen L,
Juhl CO, Poulsen SS, Djurhuus JC, Dajani EZ, Nexo E: Chronic
administration of epidermal growth factor to pigs induces growth
especially of the urinary tract with accumulation of epithelial
glycoconjugates. Lab Invest 73: 788-793,
1995.
78.
Juhl
CO, Vinter-Jensen
L, Poulsen SS, Orntoft TF, Dajani EZ: Chronic treatment with
epidermal growth factor causes esophageal hyperplasia in pigs and
rats. Dig Dis Sci
40: 2717-2723, 1995.
79.
Dajani EZ: Prostaglandins, NSAIDs and gastrointestinal
mucosal injury: Can we identify patients at risk of NSAID-induced
gastric injury? An Editroial. Am J Gastroenterol 91 (5): 835-836, 1996.
80. Vega KJ, Bollu
J, Dajani EZ, Trotman BW: Idiopathic esophageal ulceration in HIV
patients. J Assoc Acad Min Phycians 74 (4): 93-98,
1996.
81.
Vinter-Jensen L, Juhl CO, Frystyk J, Dajani EZ,
Oksbjerg N, FlyvbergN: The effects of epidermal growth
factor
(EGF) on circulating levels on insulin like growth factor
I(IGF-I) and IGF binding
proteins (IGFBPs) in adult Goettingen
minipigs. J Endocrinol 151: 401- 407,
1996.
82.
Gregersen H, Vinter-Jensen L, Juhl CO, Dajani EZ: Impedance
planimetric characterization of distal esophagus in the Goettingen
minipigs. J Biomech 29: 63-68,
1996.
83.
Vinter-Jensen L,
Juhl CO, Dajani EZ, Nielsen M, Djurhuus JC: Chronic systemic
treatment with epidermal growth factor induces smooth muscle cell
hyperplasia and hypertrophy in the urinary tract of mature
Goettingen minipigs. British J Urology 79: 532-538,
1997.
84.
Vinter-Jensen L,
Juhl CO, Stubbe P, Poulsen SS, Nexo E: Systemic treatment with
epidermal growth factor in pigs induces induces ductal
proliferations in the pancreas. Gastroenterology 113:
1367-1374, 1997.
85.
Dajani EZ: Gastrointestinal Toxicity of
over-the-
counter analgesics. An Editorial. Am J Gastroenterol
93(7):
1020-1022, 1998.
86.
Larsen KR, Dajani EZ,
Dajani
NE,
Dayton
MT, Moore JG:
Effects of tolcapone, a catechol-o-methyl transferase
inhibitor,
and
Sinemet on intestinal electrolyte and fluid transport in
conscious dogs. Dig Dis Sci 43(8): 1806-1813,
1998.
87. Adeoti AG, Vega
KJ, Dajani EZ, Trotman BW, Kloser PC: Idiopathic esophageal
ulcerations in HIV infected patients. Successful treatment with
misoprostol and viscous Lidocaine. Am J Gastroenterol 93(11):
2069-2074, 1998.
88.
Dajani EZ,
Larsen KR, Taylor J, Dajani NE, Shahwan TG, Neeleman SD, Taylor MS,
Dayton MT, Mir GN: CT-3
[1’1’-dimethyl-heptyl-Delta-8-THC-11-oic acid]: A novel, orally
effective cannabinoid with analgesic and anti-inflammatory
properties. J Pharmacol Exp Therap 291: 31-38,
1999.
89. Dajani EZ:
Gastroesophageal reflux disease (GERD): Pathophysiological and
pharmacological considerations. J Assoc Acad Min Physicians
11: 7-11, 2000.
90. Trotman BW,
Boyce JG, Dajani EZ, Kamholz SL, Rayford PL, Scott VF: Highlights of
the 13th Annual Scientific Meeting of the Association for
Academic Minority Physicians. J Assoc Acad Min Physicians 11:
3-5, 2000.
91.
Dajani EZ,
Klamut M: Therapeutic approaches for gastric and duodenal ulcers: An
update. Expert Opinion on Investigational Drugs 90:
1537-1544, 2000.
92.
Dajani EZ,
Agrawal
NM: Selective
COX-2 inhibitors and gastrointestinal mucosal injury:
Pharmacological and therapeutic considerations. J Assoc Acad Min
Physicians 11: 28-31, 2000.
93.
Trotman BW,
Boyce JG, Dajani EZ, Davidson EC, Scott VF: Highlights of the
14th Annual Scientific Meeting of the Association for
Academic Minority Physicians, 2000. J Assoc Acad Min Physicians
12: 95-97, 2001.
94.
Dajani EZ,
Shahwan TG, Dajani,
NE: Statins,
platelet aggregation and coronary heart disease. J
Assoc Acad Min Physicians 13: 27-31,
2002.
95.
Trotman BW,
Scott VF, Dajani EZ, Davidson EC, Kamholz SL: Highlights of the
15th Annual Scientific Meeting of the Association for
Academic Minority Physicians, 2001. J Assoc Acad Min Physicians
13: 6-8, 2002.
96.
Dajani EZ, Shahwan T,
Dajani
NE: Prostaglandins and brain-gut
axis. J Physiology and Pharmacology
54:155-164,2003.
97. Dajani EZ, Konturek SJ: Brain-gut axis in gastrointestinal
system: Concluding remarks. J Physiology and Pharmacology
54:3-9,2003.
98.
Dajani EZ, Dajani ME: Are U.S. cosmetic regulatory policies keeping
consumers safe? Update. Food and Drug Laws
6: ( November/Deceber):22-24,
2005.
99.
Dajani EZ,
Agrawal
NM: NSAIDs, H. pylori and
gastrointestinal ulceration. Medical Science Monitor (In
Press).
IDDC
Corporation
1549
Chickamauga
Lane
Long
Grove,
Illinois
60647-9532
Phone:
847-634-9586
Fax:
773-477-5736
E-mail: EsamD@aol.com & EsamD@comcast.net
| 
